Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Date:10/26/2009

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Select Medical Holdings Corporation Announces Exercise of Underwriters Option to Purchase Additional Shares
7. Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
8. Mirixa Corporation Announces MirixaEdge(SM)
9. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... January 13, 2017 Constant research ongoing ... will collectively contribute to the demand for western blotting technique. ... value of US$ 551.0 Mn by 2016 end. Developing economies ... most lucrative markets for western blotting, whereas North ... ...
(Date:1/13/2017)... NEW YORK , January 13, 2017 ... Biotech equities to see how they have fared at ... CLVS ), Galena Biopharma Inc. (NASDAQ: GALE ... ). These companies harness cellular and biomolecular processes to ... diseases, reduce our environmental footprint, feed the hungry, use ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... ... physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted ... managing the award process. Results were announced the magazine’s January 2017 issue ...
(Date:1/14/2017)... ... 14, 2017 , ... Healthy living brand Moody Zook recently ... products. With more and more people opting to go organic in their lifestyle, ... cater to specific needs. , Moody Zook focused particularly on their newly launched ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... sugar levels. Counting carbohydrates is as easy as checking the nutrition label on ... affects blood sugar levels. Despite being sugar-free, proteins can influence — either positively ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public preference ... providing additional organic alternatives for customers who have grown more conscious about maintaining ... of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained ...
(Date:1/13/2017)... ... ... "We wanted to create a design for orthodontic appliances that would make ... Beach, Va. , They created a prototype for the patent-pending BRACE FACERS to add ... be customized to suit personal tastes. They can be used to create custom designs ...
Breaking Medicine News(10 mins):